ArticleJournal of the American Society of Nephrology : JASN2026
Tubular La Ribonucleoprotein 7 Suppresses TGF- β /SMAD3 Signaling and Attenuates Kidney Fibrogenesis.
Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-omics and machine learning reveal LYZ and ISG15 as diagnostic and therapeutic targets in autoimmune-mediated chronic kidney disease.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
key pointsLARP7 suppresses TGF- β /SMAD3-driven fibrosis by sequestering CDK9, which inhibits SMAD3 T179 phosphorylation and profibrotic transcription. TGF- β 1 represses LARP7 expression in injured tubules, establishing a self-reinforcing loop that amplifies and sustains fibrogenic signaling. Tubule-specific LARP7 restoration interrupts this vicious cycle, attenuates SMAD3 activity, and confers protection against kidney fibrosis in vivo .
backgroundTGF- β 1/SMAD3 signaling drives organ fibrosis, underscoring the need to identify its endogenous regulators for precision therapies. LARP7, a core component of the 7SK snRNP complex that sequesters cyclin-dependent kinase 9, has an unexplored role in kidney fibrosis and a potential interplay with TGF- β /SMAD3 signaling.
methodsSingle-cell and spatial transcriptomic analyses combined with immunostaining of human kidney biopsies were used to investigate the association between LARP7 and TGF- β /SMAD3 signaling in patients with CKD. In vivo and in vitro models evaluated the expression profile of LARP7 after insults and its contribution to TGF- β /SMAD3 signaling and fibrosis postinjury.
resultsWe demonstrated that LARP7, abundantly expressed in normal tubules, was downregulated in CKD patients and inversely correlated with TGF- β /SMAD3 activation. This expression pattern was conserved across ischemic, toxic, and obstructive fibrosis models and recapitulated in TGF- β 1-treated tubular epithelial cells, indicating a general link between LARP7 downregulation and enhanced TGF- β /SMAD3 signaling. Further loss-of-function and gain-of-function in vitro studies confirmed that LARP7 acted as a specific disruptor of SMAD3 linker region (T179) phosphorylation-an event that coincided with C -terminal phosphorylation and amplified SMAD3 transcriptional activity. LARP7 mediated this by sequestering CDK9 within the 7SK snRNP, thereby preventing CDK9-SMAD3 interaction and consequently inhibiting SMAD3 T179 phosphorylation and profibrotic transcription. TGF- β 1 itself suppressed LARP7 expression, completing a self-reinforcing feedback loop that perpetuates TGF- β /SMAD3 signaling in injured tubular epithelial cells. Further in vivo studies showed that tubule-specific Larp7 deletion exacerbated kidney fibrosis after ischemic injury, whereas its overexpression, either preventatively (prefibrosis in an obstructive model) or therapeutically (postfibrosis in ischemic and toxic models), attenuated functional decline and halted fibrotic progression.
conclusionsOur findings revealed tubular LARP7 as a key negative regulator of TGF- β /SMAD3-driven kidney fibrogenesis. Targeted overexpression of LARP7 in injured tubular epithelial cells attenuated TGF- β 1/SMAD3 signaling and conferred protection against postinjury fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.